The US Federal Trade Commission has ordered an investigation into 22 drug manufacturers, to discover whether they engaged in "unlawful concerted activities to raise, fix, maintain or stabilize the prices" of drugs.
The probe follows the settlement of a class-action lawsuit in february by independent pharmacies, claiming that 13 drug firms had conspired to overcharge them in order to cover the massive discounts offered to managed care organizations and mail-order pharmacy businesses (Marketletters passim). The companies under investigation include American Home Products, Glaxo Wellcome, Lilly, Johnson & Johnson, Pfizer, Sandoz, Schering-Plough, SmithKline Beecham and Warner-Lambert.
Local reports note that the investigation is less concerned with price discounting than with the allegations that the companies conspired to manipulate prices, thus contravening federal antitrust legislation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze